Juvenile dermatomyositis(JDM)is a chronic pediatric autoimmune disease characterized by proximal muscle weakness and distinctive skin manifestations[1,2].The first-line treatment for JDM involves the combination of gl...Juvenile dermatomyositis(JDM)is a chronic pediatric autoimmune disease characterized by proximal muscle weakness and distinctive skin manifestations[1,2].The first-line treatment for JDM involves the combination of glucocorticoids with either methotrexate(MTX)or cyclosporine[3,4].For severe and refractory juvenile dermatomyositis,options such as tacrolimus.展开更多
基金supported by the National Key R&D Program of China(Grant No.2021YFC2702001)Project supported by the Young Scientists Fund of the National Natural Science Foundation of China(Grant No.82101423).
文摘Juvenile dermatomyositis(JDM)is a chronic pediatric autoimmune disease characterized by proximal muscle weakness and distinctive skin manifestations[1,2].The first-line treatment for JDM involves the combination of glucocorticoids with either methotrexate(MTX)or cyclosporine[3,4].For severe and refractory juvenile dermatomyositis,options such as tacrolimus.
